NCT03737994 2026-03-18
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT04318938 2026-03-02
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT05721950 2026-02-18
Brilliant
Takeda
Active not recruiting
NCT04223596 2026-02-04
CUBIK
Fundación GECP
Phase 2 Active not recruiting
NCT05200481 2025-11-17
MP-ALK
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Active not recruiting
NCT03707938 2025-11-03
Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04227028 2025-09-16
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC
City of Hope Medical Center
Phase 1 Active not recruiting